Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q4 EPS of ($0.92), $0.15 worse than the analyst estimate of ($0.77).

For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.